Predicting contrast induced nephropathy post coronary intervention: A prospective cohort study

Egyptian Heart Journal

Volumn 67, Issue 4, 2015, Pages 337-343

  Shams Eddin Taher, Hamdy ^a   Hassan, Ayman K M ^a   Dimitry, Salwa R ^a   Mahfouz, Amir K ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

Contrast induced nephropathy; Ischemic heart disease; Percutaneous coronary intervention

Indexed keywords

CREATININE;

ACUTE KIDNEY FAILURE; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTRAST INDUCED NEPHROPATHY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNIVERSITY HOSPITAL;

EID: 84947485037     PISSN: 11102608     EISSN: 2090911X     Source Type: Journal    
DOI: 10.1016/j.ehj.2015.02.001     Document Type: Article

References (36)

1. Tziakas D., Chalikias G., Stakos D., et al. Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention. Am J Cardiol 2014, 113:1487-1493.
2. McCullough P.A. Beyond serum creatinine: defining the patient with renal insufficiency and why?. Rev Cardiovasc Med 2003, 4(Suppl 1):S2-S6.
3. Bartorelli A.L., Marenzi G. Contrast-induced nephropathy. J Interv Cardiol 2008, 21:74-85.
4. Bellin M.F., Jakobsen J.A., Tomassin I., et al. Contrast medium extravasation injury: guidelines for prevention and management. Eur Radiol 2002, 12:2807-2812.
5. Iakovou I., Dangas G., Mehran R., et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003, 15:18-22.
6. Gruberg L., Mintz G.S., Mehran R., et al. The prognostic implications of further renal function deterioration within 48h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36:1542-1548.
7. Mehran R., Aymong E.D., Nikolsky E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004, 44:1393-1399.
8. McCullough P.A. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008, 51:1419-1428.
9. Wright R.S., Anderson J.L., Adams C.D., et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011, 57:1920-1959.
10. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39. S1-266.
11. Rule A.D., Larson T.S., Bergstralh E.J., et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Int Med 2004, 141:929-937.
12. Nash K., Hafeez A., Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002, 39:930-936.
13. Bouzas-Mosquera A., Vazquez-Rodriguez J.M., Calvino-Santos R., et al. Contrast-induced nephropathy and acute renal failure following emergent cardiac catheterization: incidence, risk factors and prognosis. Rev Esp Cardiol 2007, 60:1026-1034.
14. Mehran R., Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006, S11-S15.
15. Zaki T., Samir A., Mohammed Rashid T., et al. Assessment of estimated GFR and clinical predictors of contrast induced nephropathy among diabetic patients undergoing cardiac catheterization. The Egypt Heart J 2015, 67:249-258.
16. Galal H., El Nammas W., Samir A. Impact of high dose versus low dose atorvastatin on contrast induced nephropathy in diabetic patients with acute coronary syndrome undergoing early percutaneous coronary intervention. The Egypt Heart J 2015, 67:329-336.
17. Ayad S.W., Sobhy M.A., Sadaka M.A., et al. Impact of left ventricular end diastolic pressure guided hydration on prevention of contrast induced nephropathy post cardiac catheterization. The Egypt Heart J 2015, 67:325-328.
18. Rihal C.S., Textor S.C., Grill D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259-2264.
19. Gruberg L., Mintz G.S., Mehran R., et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001, 52:409-416.
20. Solomon R.J., Mehran R., Natarajan M.K., et al. Contrast-induced nephropathy and long-term adverse events: cause and effect?. Clin J Am Soc Nephrol 2009, 4:1162-1169.
21. Manske C.L., Sprafka J.M., Strony J.T., et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990, 89:615-620.
22. Cigarroa R.G., Lange R.A., Williams R.H., et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989, 86:649-652.
23. Liu Y., Tan N., Zhou Y.L., et al. The contrast medium volume to estimated glomerular filtration rate ratio as a predictor of contrast-induced nephropathy after primary percutaneous coronary intervention. Int Urol Nephrol 2012, 44:221-229.
24. Laskey W.K., Jenkins C., Selzer F., et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007, 50:584-590.
25. McClennan B.L. Low-osmolality contrast media: premises and promises. Radiology 1987, 162:1-8.
26. Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Interv Radiol 2005, 28(Suppl 2):S3-S11.
27. Chang CF, Lin CC. Current concepts of contrast-induced nephropathy: A brief review. J Chinese Med Assoc 76: p. 673-81.
28. Barrett B.J., Carlisle E.J. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993, 188:171-178.
29. Reed M., Meier P., Tamhane U.U., et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2009, 2:645-654.
30. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005, 68:2256-2263.
31. Persson P.B., Hansell P., Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005, 68:14-22.
32. Kushner F.G., Hand M., Smith S.C., et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009, 54:2205-2241.
33. Moos S.I., Nagan G., de Weijert R.S., et al. Patients at risk for contrast-induced nephropathy and mid-term effects after contrast administration: a prospective cohort study. Neth J Med 2014, 72:363-371.
34. Moos S.I., de Weijert R.S., Nagan G., et al. Cost of screening strategies for kidney disease before intravenous contrast administration. Neth J Med 2014, 72:271-280.
35. Moore R.D., Steinberg E.P., Powe N.R., et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 1992, 182:649-655.
36. Marenzi G., Lauri G., Assanelli E., et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004, 44:1780-1785.